Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Maysa Vilbert"'
Autor:
Jonathan N. Priantti, Maysa Vilbert, Francisco Cezar Aquino de Moraes, Thiago Madeira, Evair Moisés de Lima Santiago, Natasha B. Leighl, Ludimila Cavalcante, Nagla F. Abdel Karim
Publikováno v:
Cancers, Vol 16, Iss 14, p 2611 (2024)
Lorlatinib has been FDA-approved as a systemic therapy for ALK/ROS1-positive non-small cell lung cancer (NSCLC) patients. However, it has been associated with an increased frequency of neurocognitive adverse events (NAEs). Therefore, we conducted a s
Externí odkaz:
https://doaj.org/article/8273f4afd89a4b54921bb9d74ef84b89
Autor:
Isabella Michelon, Maysa Vilbert, Caio Ernesto do Rego Castro, Carlos Stecca, Maria Inez Dacoregio, Manglio Rizzo, Vladmir Cláudio Cordeiro de Lima, Ludimila Cavalcante
Publikováno v:
Journal of Personalized Medicine, Vol 14, Iss 7, p 752 (2024)
We performed a systematic review and meta-analysis to assess the efficacy of EGFR-tyrosine kinase inhibitors (TKI) retreatment in advanced/metastatic non-small-cell lung cancer (NSCLC) patients. We systematically searched PubMed, Embase, Cochrane dat
Externí odkaz:
https://doaj.org/article/3dc65b7c282d43a3ab84eb390d477251
Autor:
Isabella Michelon, Maysa Vilbert, Isabella Silveira Pinheiro, Isabela Lino Costa, Cecilia Fernandes Lorea, Mathias Castonguay, Thai Hoa Tran, Stéphanie Forté
Publikováno v:
EClinicalMedicine, Vol 66, Iss , Pp 102330- (2023)
Summary: Background: Clinical manifestations and severity of SARS-CoV-2 infection in individuals with sickle cell disease (SCD) and sickle cell trait (SCT) are not well understood yet. Methods: We performed a systematic review and meta-analysis to as
Externí odkaz:
https://doaj.org/article/ceb1342190ef401d8d05305722ba59d0
Autor:
Francisco Cezar Aquino de Moraes, Gustavo de Oliveira Almeida, Vinícius Freire Costa Alves, Jonathan N. Priantti, Giovanna da Conceição Gomes, Sarah Vitória Bristot Carnevalli, Thiago Madeira, Maysa Vilbert, Carlos Stecca, Maria Cristina Figueroa Magalhães, Marianne Rodrigues Fernandes, Ney Pereira Carneiro dos Santos
Publikováno v:
Journal of Personalized Medicine, Vol 14, Iss 5, p 464 (2024)
Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are approved for advanced breast cancer combined with endocrine therapy (ET). The efficacy of CDK4/6 inhibitors plus ET in hormone estrogen-positive, human epidermal growth factor 2-negative
Externí odkaz:
https://doaj.org/article/900d0596270743c994c6591b68314838
Autor:
Francisco Cezar Aquino de Moraes, Maysa Vilbert, Vinícius Freire Costa Alves, Gustavo de Oliveira Almeida, Jonathan N. Priantti, Thiago Madeira, Carlos Stecca, Marianne Rodrigues Fernandes, Ney Pereira Carneiro dos Santos
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 24, p 17582 (2023)
Papillary subtypes of renal-cell carcinoma (pRCC) represent 10–15% of the cases and commonly have MET alterations. This systematic review and single-arm meta-analysis evaluated MET inhibitor therapy (METi) efficacy and safety in adults with confirm
Externí odkaz:
https://doaj.org/article/683dc350e30d4a87ba3b3507ffb8f044
Autor:
Isabella Ferreira Michelon, Isabella Silveira Pinheiro, Isabela Lino Costa, Maysa Vilbert, Cecilia Fernandes Lorea, Mathias Castonguay, Thai Hoa Tran, Stéphanie Forté
Publikováno v:
HemaSphere, Vol 7, p e9513186 (2023)
Externí odkaz:
https://doaj.org/article/cbe02a0323ce40a1a7298a39414edb41
Publikováno v:
Cancers, Vol 15, Iss 19, p 4808 (2023)
In the field of oncology, the Signaling Lymphocyte Activation Molecule (SLAM) family is emerging as pivotal in modulating immune responses within tumor environments. The SLAM family comprises nine receptors, mainly found on immune cell surfaces. Thes
Externí odkaz:
https://doaj.org/article/1d827a2e28da4b1f91eaf81f37a2e280
Autor:
Erica C. Koch Hein, Maysa Vilbert, Ian Hirsch, Mauricio Fernando Ribeiro, Thiago P. Muniz, Cynthia Fournier, Khaled Abdulalem, Erick F. Saldanha, Erika Martinez, Anna Spreafico, David H. Hogg, Marcus O. Butler, Samuel D. Saibil
Publikováno v:
Cancers, Vol 15, Iss 17, p 4312 (2023)
Immune checkpoint inhibitors (ICI) cemiplimab and pembrolizumab have revolutionized the treatment of advanced cutaneous squamous cell carcinoma (cSCC). We aimed to evaluate the effectiveness and safety of ICI in a real-world cSCC population, includin
Externí odkaz:
https://doaj.org/article/c51c397835ed4012a1296160fefba4e6
Autor:
Jonathan N. Priantti, Maysa Vilbert, Thiago Madeira, Francisco Cezar A. Moraes, Erica C. Koch Hein, Anwaar Saeed, Ludimila Cavalcante
Publikováno v:
Cancers, Vol 15, Iss 15, p 3754 (2023)
This systematic review and meta-analysis aims to evaluate the efficacy and safety of rechallenging advanced melanoma patients with BRAFi/MEKi. Seven studies, accounting for 400 patients, were included. Most patients received immunotherapy before the
Externí odkaz:
https://doaj.org/article/6e13b41490e240659513bbefbe204f5b
Autor:
Maysa Vilbert, Erica C. Koch, April A. N. Rose, Rob C. Laister, Diana Gray, Valentin Sotov, Susanne Penny, Anna Spreafico, Devanand M. Pinto, Marcus O. Butler, Samuel D. Saibil
Publikováno v:
Cancers, Vol 15, Iss 14, p 3708 (2023)
Cutaneous melanoma (CM) patients respond better to immune checkpoint inhibitors (ICI) than mucosal and uveal melanoma patients (MM/UM). Aiming to explore these differences and understand the distinct response to ICI, we evaluated the serum metabolome
Externí odkaz:
https://doaj.org/article/5629b1e6c96b4cab9263690d11aec22a